Practical Recommendations for Clinicians Given the inconclusive data on bone safety during GLP1 treatment, clinicians should: Assess fracture risk using tools like FRAX before starting therapy Order BMD tests for patients with osteoporosis risk factors Monitor for excessive or rapid weight loss that may compromise bone mass Promote calcium and vitamin D intake, resistance training, and fall prevention strategies Refer to endocrinologists or bone specialists as needed for complex cases Future Research Questions Several questions remain unanswered about how GLP1 medications influence longterm bone integrity: Do individual GLP1 agents differ in their effects on bone remodeling
Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death
In our article about arm pain after COVID shots, we received a number of comments complaining of longer-lasting pain
Carnitine deficiency can be caused by a genetic fault in the carnitine transporter protein, dietary issues, metabolic disorders, kidney dysfunction, liver conditions, and certain medications
instead, it may help provide context for why an individual might respond differently to GLP-1 therapy and can support more informed dosing and medication selection conversations